BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 14979058)

  • 1. [Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives].
    Meyer O
    Bull Acad Natl Med; 2003; 187(5):935-54; discussion 954-5. PubMed ID: 14979058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TNF-alpha transgenic mouse model of inflammatory arthritis.
    Li P; Schwarz EM
    Springer Semin Immunopathol; 2003 Aug; 25(1):19-33. PubMed ID: 12904889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes.
    Xu H; He Y; Yang X; Liang L; Zhan Z; Ye Y; Yang X; Lian F; Sun L
    Rheumatology (Oxford); 2007 Jun; 46(6):920-6. PubMed ID: 17314215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies.
    Ribbens C; André B; Kaye O; Kaiser MJ; Bonnet V; de Groote D; Franchimont N; Malaise MG
    Eur Cytokine Netw; 2000 Dec; 11(4):669-76. PubMed ID: 11125312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mode of action of cytokine inhibitors.
    Arend WP
    J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-hydroxyfrullanolide, a sesquiterpene lactone, inhibits pro-inflammatory cytokine production from immune cells and is orally efficacious in animal models of inflammation.
    Fonseca LC; Dadarkar SS; Lobo AS; Suthar AC; Chauhan VS; Chandrababu S; Sharma SD; Dagia NM; Padigaru M
    Eur J Pharmacol; 2010 Oct; 644(1-3):220-9. PubMed ID: 20621086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.
    Williams LM; Gibbons DL; Gearing A; Maini RN; Feldmann M; Brennan FM
    J Clin Invest; 1996 Jun; 97(12):2833-41. PubMed ID: 8675695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytokines and anti-cytokines in inflammatory rheumatism].
    Dayer JM
    Rev Rhum Ed Fr; 1994 Dec; 61(10 Pt 2):173S-180S. PubMed ID: 7858569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF alpha as a therapeutic target in rheumatoid arthritis.
    Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN
    Circ Shock; 1994 Aug; 43(4):179-84. PubMed ID: 7895323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
    Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
    Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
    Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
    J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-inflammatory properties of interleukin-4].
    Miossec P
    Rev Rhum Ed Fr; 1993 Feb; 60(2):119-24. PubMed ID: 8136803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
    Vandooren B; Cantaert T; van Lierop MJ; Bos E; De Rycke L; Veys EM; De Keyser F; Bresnihan B; Luyten FP; Verdonk PC; Tak PP; Boots AH; Baeten D
    Ann Rheum Dis; 2009 Jun; 68(6):1044-50. PubMed ID: 18633128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL.
    Hui W; Cawston TE; Richards CD; Rowan AD
    Arthritis Res Ther; 2005; 7(1):R57-64. PubMed ID: 15642143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors.
    Hale KK; Smith CG; Baker SL; Vanderslice RW; Squires CH; Gleason TM; Tucker KK; Kohno T; Russell DA
    Cytokine; 1995 Jan; 7(1):26-38. PubMed ID: 7749064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
    Fenner H
    Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A; Hasegawa K; Suguro T; Koshihara Y
    J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission of collagen-induced arthritis is associated with high levels of transforming growth factor-beta expression in the joint.
    Marinova-Mutafchieva L; Gabay C; Funa K; Williams RO
    Clin Exp Immunol; 2006 Nov; 146(2):287-93. PubMed ID: 17034581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.